BURLINGAME, Calif.--(BUSINESS WIRE)--Genesis Therapeutics, a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients, announced today a further equity investment from NVentures, NVIDIA’s venture capital arm. This investment is in addition to NVentures’ participation in the company’s $200 million Series B financing in August 2023..

加利福尼亚州伯灵格姆讯（商业新闻短讯）--Genesis Therapeutics是一家开创人工智能（AI）技术为患者创造突破性药物的公司，今天宣布由NVIDIA的风险投资部门NVentures进行进一步的股权投资。

Genesis is collaborating with NVIDIA to accelerate Genesis’ AI platform, GEMS (Genesis Exploration of Molecular Space). Genesis will leverage NVIDIA’s expertise to make computation more efficient for several neural network architectures relevant to drug discovery. The collaboration will, among other areas, encompass optimizing equivariant neural networks, which are valuable for handling 3D geometric data such as protein and small molecule structures..

Genesis正在与NVIDIA合作，以加速Genesis的AI平台GEMS（Genesis Exploration of Molecular Space）。Genesis将利用NVIDIA的专业知识，使与药物发现相关的几种神经网络架构的计算效率更高。除其他领域外，该合作将包括优化等变神经网络，这对于处理蛋白质和小分子结构等3D几何数据很有价值。

“We look forward to combining our expertise and resources with NVIDIA’s to help realize our vision of harnessing AI to generate breakthrough therapies for diseases with high unmet need,” said Evan Feinberg, Ph.D., founder and CEO of Genesis. “Addressing previously undruggable targets to create new medicines requires pioneering algorithms for drug discovery and fundamental infrastructure innovation.

Genesis创始人兼首席执行官埃文·范伯格（EvanFeinberg）博士说：“我们期待着将我们的专业知识和资源与NVIDIA结合起来，帮助实现我们利用人工智能为高度未满足需求的疾病提供突破性治疗的愿景。”

Working with NVIDIA, we will further the capabilities of our field-leading physical AI platform for structure-driven drug design.”.

与NVIDIA合作，我们将进一步提高我们领域领先的物理AI平台在结构驱动药物设计方面的能力。”

“AI serves as a tool for discovering new therapies to treat diseases,” said Mohamed “Sid” Siddeek, corporate vice president at NVIDIA and head of NVentures. “Genesis’ AI platform, and related computational advancements developed in collaboration with NVIDIA, will help deliver novel generative and predictive AI techniques to explore untapped chemical pathways and identify drug candidates.”.

NVIDIA公司副总裁兼NVentures负责人Mohamed“Sid”Siddeek表示：“人工智能是发现治疗疾病新疗法的工具。”。“Genesis的人工智能平台以及与NVIDIA合作开发的相关计算进展将有助于提供新颖的生成和预测人工智能技术，以探索未开发的化学途径并确定候选药物。”

About Genesis Therapeutics

关于Genesis Therapeutics

Genesis Therapeutics is an AI-focused biotechnology company leveraging its generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space) for small molecule drug discovery. GEMS integrates proprietary AI methods, including language models, diffusion models, and physical ML simulations, to generate and optimize molecules for complex targets.

。GEMS集成了专有的AI方法，包括语言模型，扩散模型和物理ML模拟，以生成和优化复杂目标的分子。

Genesis has raised over $300 million from leading life science, tech, and AI-focused investors, and is building a therapeutic pipeline for a variety of high-impact targets. Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. For more information on Genesis, please visit the company’s website at www.genesistherapeutics.ai..

Genesis从领先的生命科学、技术和人工智能投资者那里筹集了3亿多美元，并正在为各种高影响力目标建立治疗渠道。Genesis总部位于加利福尼亚州伯灵格姆，在圣地亚哥有一个完全集成的实验室。有关Genesis的更多信息，请访问公司网站www.genesistherapeutics.ai。